Form EFFECT Nuwellis, Inc.
Tweet
Share
E-mail| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 4, 2026 5:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Study supports epoprostenol as anticoagulant in pediatric Aquadex therapy
- Sangfor Technologies Included in the 2026 Gartner® Magic Quadrant™ for SASE Platforms
- Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
